Neuroscience

Must know

• Dopamine (DA) — Reward and MotorCell body origin: Dopamine cell bodies are concentrated in the substantia nigra, ventral tegmental area, and arcuate nucleus.

  • Cell body origin: Dopamine cell bodies are concentrated in the substantia nigra, ventral tegmental area, and arcuate nucleus.
  • Receptor architecture: There are 5 dopamine receptor subtypes split into the D1-like family (D1, D5) and the D2-like family (D2, D3, D4).
  • Mesolimbic pathway: Governs reward, mood, and substance abuse; excessive dopamine here causes positive symptoms of schizophrenia like hallucinations and delusions.
  • Nigrostriatal pathway: Controls voluntary and involuntary motor movement; degeneration or heavy blockade leads to drug-induced parkinsonism, dyskinesias, and extrapyramidal symptoms.
  • Mesocortical pathway: Mediates executive function, planning, and cognition; dopamine deficits here drive negative symptoms of schizophrenia.
  • Tuberoinfundibular pathway: Projects to the pituitary gland to inhibit prolactin; D2 blockade causes hyperprolactinemia, galactorrhea, and sexual dysfunction.
• Four Dopamine Pathways and Clinical MappingMesolimbic pathway: Arises from the VTA and projects into the limbic system. It regulates reward-seeking behavior, mood, and addiction. Excessive dopamine activity in this tract produces positive psychotic symptoms, including delusions and hallucinations.

  • Mesolimbic pathway: Arises from the VTA and projects into the limbic system. It regulates reward-seeking behavior, mood, and addiction. Excessive dopamine activity in this tract produces positive psychotic symptoms, including delusions and hallucinations.
  • Nigrostriatal pathway: Arises from the substantia nigra and projects to the striatum. It controls voluntary and involuntary motor function. Neuronal loss or drug blockade in this pathway causes parkinsonism, dyskinesia, and extrapyramidal adverse effects.
  • Mesocortical pathway: Projects from the VTA to the prefrontal cortex. It governs cognitive planning, behavior, and executive function. Dopamine deficiency in this pathway causes executive dysfunction and negative symptoms of schizophrenia.
  • Tuberoinfundibular pathway: Projects from the arcuate nucleus to the anterior pituitary gland. Dopamine acts as a tonic prolactin-inhibiting factor here. Interruption of this tract causes serum prolactin levels to rise.
• Key Pharmacologic AgentsRisperidone: An SGA with potent D2 blockade that frequently disrupts the tuberoinfundibular pathway, triggering hyperprolactinemia, galactorrhea, and sexual dysfunction.

  • Risperidone: An SGA with potent D2 blockade that frequently disrupts the tuberoinfundibular pathway, triggering hyperprolactinemia, galactorrhea, and sexual dysfunction.
  • Bupropion: A selective norepinephrine-dopamine reuptake inhibitor (NDRI) that boosts dopamine and norepinephrine levels to treat major depressive disorder and assist smoking cessation.
  • Methylphenidate: A psychostimulant that increases dopamine and norepinephrine concentrations at the synapse to treat ADHD.
• Mesolimbic vs. Mesocortical PathwaysThink: Mesolimbic equals positive symptoms and reward, while mesocortical equals negative symptoms and cognition.

  • Think: Mesolimbic equals positive symptoms and reward, while mesocortical equals negative symptoms and cognition.
  • Priority: Excessive dopamine in the mesolimbic tract requires D2 receptor blockade to stop active psychosis. Dopamine deficiency in the mesocortical tract causes cognitive impairment, avolition, and emotional flattening.
  • Boards are testing: Blocking D2 receptors in the mesolimbic pathway resolves hallucinations without improving mesocortical negative symptoms.
• Nigrostriatal vs. Tuberoinfundibular PathwaysThink: Nigrostriatal controls motor movement, while tuberoinfundibular controls prolactin suppression.

  • Think: Nigrostriatal controls motor movement, while tuberoinfundibular controls prolactin suppression.
  • Priority: Nigrostriatal blockade causes motor rigidity, tremors, and dyskinesia. Tuberoinfundibular blockade causes endocrine disruption, leading to galactorrhea and sexual dysfunction.
  • Boards are testing: Risperidone is the classic SGA distractor that behaves like an FGA on the tuberoinfundibular pathway, causing marked hyperprolactinemia.
• First-Generation Antipsychotics (FGAs) vs. Second-Generation Antipsychotics (SGAs)Think: FGAs hit hard and stay bound to D2 receptors, whereas SGAs dissociate rapidly or act as partial agonists.

  • Think: FGAs hit hard and stay bound to D2 receptors, whereas SGAs dissociate rapidly or act as partial agonists.
  • Priority: SGAs are preferred over FGAs primarily due to a lower risk of extrapyramidal side effects and tardive dyskinesia.
  • Boards are testing: Both classes share equal clinical efficacy in treating positive psychotic symptoms.
• Board Traps and Distractor LogicSGAs are the first-line choice for schizophrenia management because their rapid receptor dissociation minimizes motor toxicity while maintaining mesolimbic D2 blockade.

  • Test writers will suggest that SGAs are superior to FGAs because they have higher clinical efficacy. The board reality is that overall antipsychotic efficacy for positive symptoms is identical between classes; SGAs are chosen solely for their lower rate of extrapyramidal adverse effects.
  • Blocking dopamine in the nigrostriatal pathway with high-potency FGAs causes acute motor reactions, including dystonia, akathisia, and drug-induced parkinsonism.
  • SGAs are the first-line choice for schizophrenia management because their rapid receptor dissociation minimizes motor toxicity while maintaining mesolimbic D2 blockade.

  Board trap. Test writers will suggest that SGAs are superior to FGAs because they have higher clinical efficacy. The board reality is that overall antipsychotic efficacy for positive symptoms is identical between classes; SGAs are chosen solely for their lower rate of extrapyramidal adverse effects.

  Safety. Blocking dopamine in the nigrostriatal pathway with high-potency FGAs causes acute motor reactions, including dystonia, akathisia, and drug-induced parkinsonism.

• Norepinephrine (NE) — AlertnessCell bodies for norepinephrine neurons are located in the locus coeruleus of the pons.

  • Cell bodies for norepinephrine neurons are located in the locus coeruleus of the pons.
  • Norepinephrine mediates alertness, focused attention, vigilance, and the physiological fight or flight response.
  • Noradrenergic pathways innervate the amygdala and prefrontal cortex, forming the core neural circuit for anxiety and worry.
  • Dysregulation of the noradrenergic system occurs with early childhood maltreatment and is implicated in ADHD, major depressive disorder, generalized anxiety disorder, panic disorder, and PTSD.
  • Psychostimulants like methylphenidate and amphetamine increase levels of both norepinephrine and dopamine.
  • Selective norepinephrine reuptake inhibitors like atomoxetine increase norepinephrine levels specifically for ADHD.
• Locus Coeruleus and Physiological RoleNorepinephrine is a major monoamine catecholamine synthesized in the locus coeruleus, located in the pons of the brainstem. It serves as the primary neurotransmitter responsible for executive alertness, focused attention, learning, and environmental vigilance. A controlled surge of norepinephrine optimizes cognitive performance during acute tasks like taking a board exam. However, severe dysregulation triggers excessive autonomic arousal, hypervigilance, and panic.

  • Norepinephrine is a major monoamine catecholamine synthesized in the locus coeruleus, located in the pons of the brainstem. It serves as the primary neurotransmitter responsible for executive alertness, focused attention, learning, and environmental vigilance. A controlled surge of norepinephrine optimizes cognitive performance during acute tasks like taking a board exam. However, severe dysregulation triggers excessive autonomic arousal, hypervigilance, and panic.
• Psychopharmacology and Receptor DynamicsFirst-line psychostimulants, including methylphenidate and amphetamine derivatives, increase synaptic levels of both norepinephrine and dopamine to treat ADHD. Atomoxetine functions as a non-stimulant selective norepinephrine reuptake inhibitor. Bupropion acts as a dual norepinephrine and dopamine reuptake inhibitor, offering effective treatment for major depressive disorder without causing the sexual side effects or weight gain associated with serotonergic agents. Serotonin-norepinephrine reuptake inhibitors like venlafaxine and duloxetine block both serotonin and norepinephrine transporters.

  • First-line psychostimulants, including methylphenidate and amphetamine derivatives, increase synaptic levels of both norepinephrine and dopamine to treat ADHD. Atomoxetine functions as a non-stimulant selective norepinephrine reuptake inhibitor. Bupropion acts as a dual norepinephrine and dopamine reuptake inhibitor, offering effective treatment for major depressive disorder without causing the sexual side effects or weight gain associated with serotonergic agents. Serotonin-norepinephrine reuptake inhibitors like venlafaxine and duloxetine block both serotonin and norepinephrine transporters.
  • Any medication that increases norepinephrine (including SNRIs, bupropion, atomoxetine, and stimulants) can cause dose-dependent elevation in blood pressure and resting heart rate. Baseline and ongoing cardiovascular monitoring is mandatory.
  • Test writers often try to trick candidates into thinking bupropion acts on serotonin. Bupropion has no serotonergic activity. It acts exclusively on dopamine and norepinephrine.

  Board trap. Test writers often try to trick candidates into thinking bupropion acts on serotonin. Bupropion has no serotonergic activity. It acts exclusively on dopamine and norepinephrine.

  Safety. Any medication that increases norepinephrine (including SNRIs, bupropion, atomoxetine, and stimulants) can cause dose-dependent elevation in blood pressure and resting heart rate. Baseline and ongoing cardiovascular monitoring is mandatory.

• Serotonin (5-HT) — Calm and MoodCell bodies producing serotonin are concentrated in the raphe nuclei within the brainstem, and 90% of total body serotonin is located in the gastrointestinal tract.

  • Cell bodies producing serotonin are concentrated in the raphe nuclei within the brainstem, and 90% of total body serotonin is located in the gastrointestinal tract.
  • Serotonin acts as a primary calming neurotransmitter that regulates sleep, mood, appetite, and aggression, and it serves as the direct biochemical precursor to melatonin.
  • The serotonergic system contains 7 receptor families and at least 15 subfamilies, providing distinct targets for various psychotropic medication classes.
  • Selective serotonin reuptake inhibitors such as fluoxetine block the presynaptic reuptake pump, increasing serotonin availability in the synaptic cleft.
  • Key receptor subtype mechanisms include buspirone acting as a 5-HT1A partial agonist, triptans acting as 5-HT1B and 5-HT1D agonists, mirtazapine acting as a 5-HT2 and 5-HT3 antagonist, and second generation antipsychotics blocking 5-HT2A receptors.
  • Peripheral and central serotonergic stimulation causes classic adverse effects including loose stools, gastrointestinal upset, and decreased libido or sexual dysfunction.
• Anatomic Origin and Biological RoleCell bodies that synthesize and release serotonin are localized in the raphe nuclei in the brainstem.

  • Cell bodies that synthesize and release serotonin are localized in the raphe nuclei in the brainstem.
  • Approximately 90% of the body's serotonin is distributed throughout the gut, which explains why starting serotonergic agents causes acute gastrointestinal side effects.
  • Serotonin is the essential chemical precursor needed to synthesize melatonin, making it vital for normal sleep architecture.
  • It functions as a calming neurotransmitter that inhibits behavioral impulsivity, reduces aggression, and stabilizes emotional baseline.
  • Pathologic dysregulation of serotonergic neurotransmission manifests clinically as irritability, hostility, sleep disruption, anxiety, depression, and reduced sexual drive.
• Receptor Subtypes and PsychopharmacologyThe central nervous system contains 7 serotonin receptor families and at least 15 distinct subfamilies.

  • The central nervous system contains 7 serotonin receptor families and at least 15 distinct subfamilies.
  • Selective serotonin reuptake inhibitors like fluoxetine inhibit the reuptake transporter, increasing serotonin concentration within the synaptic cleft.
  • Venlafaxine functions as a dual reuptake inhibitor affecting both serotonin and norepinephrine.
  • Buspirone acts as a 5-HT1A partial agonist to treat anxiety without causing sedation or physical dependence.
  • Triptans act as 5-HT1B and 5-HT1D receptor agonists for acute migraine abortive therapy.
  • Mirtazapine provides potent receptor antagonism at 5-HT2 and 5-HT3 sites.
• Signposts and Board PearlsSelective serotonin reuptake inhibitors are first-line agents for treating major depressive disorder and anxiety disorders.

  • Selective serotonin reuptake inhibitors are first-line agents for treating major depressive disorder and anxiety disorders.
  • Do not mistake transient gastrointestinal distress or sexual dysfunction for a worsening psychiatric condition; these are expected serotonergic side effects.
  • Prescribing multiple serotonergic drugs simultaneously dramatically elevates the risk for serotonin syndrome.

  Board trap. Do not mistake transient gastrointestinal distress or sexual dysfunction for a worsening psychiatric condition; these are expected serotonergic side effects.

  Safety. Prescribing multiple serotonergic drugs simultaneously dramatically elevates the risk for serotonin syndrome.

• Match the medication **fluoxetine** with its involved primary neurotransmitterC. Norepinephrine

  • C. Norepinephrine
• Match the medication **venlafaxine** with its involved primary neurotransmittersB. Serotonin and Norepinephrine

  • B. Serotonin and Norepinephrine
  • C. Dopamine only
  • D. GABA and Dopamine